Hypertrophic Scar Clinical Trial
Official title:
Evaluating the Mechanism of Pain and Itch Reduction in Burn Scars Following Fractional Ablative CO2 Laser Treatment
NCT number | NCT04364217 |
Other study ID # | 2019P003424 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | June 25, 2020 |
Est. completion date | July 2025 |
Hypertrophic Burn Scars (HTBS) are often treated with Fractional CO2 laser therapy to improve cosmetic appearance. It has been noted that this leads to a reduction in the pain and itch associated with this type of scars. While this phenomenon is commonly described in the literature, the mechanism of pain and itch reduction in unclear. The investigators aim to better understand this process by histological evaluation of HTBS at different stages of laser treatment.
Status | Recruiting |
Enrollment | 28 |
Est. completion date | July 2025 |
Est. primary completion date | March 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - Patient must have a hypertrophic burn scar treated by skin grafts or allowed to heal secondarily - Burn must have occurred within the last 2 years from time of recruitment - Patient must have symptoms of pain and/or itch and/or hypersensitivity in the hypertrophic burn scar area - Patient must already be planning to undergo laser treatment for their burn scar - Patient must be willing to undergo biopsy procedures - Patient must be willing and able to participate in the study with a year of follow-up - Not be pregnant or planning to become pregnant during the treatment phase of the study Exclusion Criteria: - Medical Conditions that preclude laser treatment - Active tanning, including the use of tanning booths, during the course of the study - Inability to complete surveys - Previous laser (PDL, CO2), surgical reconstructive treatment procedures done on the hypertrophic burn scar - Current treatment with other procedures or drugs (experimental or other) in area of interest - Medications that interfere with wound healing (oral steroids, immunosuppressive medications, chemotherapy or other) - Medication for itch (steroids, antihistamines, or other) - Medication for pain (opioids, topical pain treatment, gabapentin, ondasetron, paroxetine or other) - Adverse reactions to topical or local anesthetic agents needed for this study, if no alternative to the said agent exists - The study area should not be part of a contracture or other hypertrophic scar that would be better treated with surgical procedures. - The study scar must not be adjacent to/in continuity with areas of HTBS that are planning to be treated with surgical interventions. - Any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject - Patient suffers from epilepsy or seizure disorder. |
Country | Name | City | State |
---|---|---|---|
United States | Massachusetts General Hospital | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Massachusetts General Hospital |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Histological change in nerve density | The investigators will stain the collected skin with markers specific to nerves to in order to count the number of nerves per biopsy area. | 7 months | |
Primary | Histological change in nerve morphology | The investigators will stain the collected skin with markers specific to nerves to in order to compare the size and shape of cutaneous nerves before and after treatment. This will be based on subjective evaluation and not a predetermined scale. | 7 months | |
Secondary | Symptomatic Improvement Assessment | Patient Reported Outcome Measures will be collected via the Patient and Observer Scar Assessment Scale (POSAS). This is a validated questionnaire that includes 5 physician-completed parameters and 6 patient-reported measures. Each parameter is rated from 1-10 with a score of 1 representing "skin that appears close to normal" and 10 representing the "worst scare imaginable". Overall, the final score will range from 11( best outcome) to 110 (worst outcome).
Physician parameters relate to the scar appearance such as color and thickness of the scar; while the patient-reported parameters also include symptomatic factors, such as degree of pain associated with the scar |
7 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03376620 -
Role of Topical Putrescine (Fibrostat) for Prevention of Hypertrophic Scars in Mammoplasty Patients
|
Phase 3 | |
Terminated |
NCT03935594 -
Use of Autologous Platelet-Rich Plasma to Treat Hypertrophic Burn Scars
|
Phase 2 | |
Recruiting |
NCT03561376 -
Zinc Oxide Versus Petrolatum Following Skin Surgery
|
Early Phase 1 | |
Recruiting |
NCT06033430 -
Effectiveness of Dry Needling in Linear Scar Tissue
|
N/A | |
Recruiting |
NCT03631368 -
Treatment of Hypertrophic Scars With Intradermal Botox
|
Phase 2 | |
Completed |
NCT03630198 -
Pain Outcomes Following Intralesional Corticosteroid Injections
|
Phase 4 | |
Recruiting |
NCT02168634 -
The Use of Botulinum Toxin in the Treatment of Itching From Hypertrophic Scar -- A Randomised Controlled Trial
|
N/A | |
Completed |
NCT02030275 -
A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery in Healthy Adults
|
Phase 2 | |
Recruiting |
NCT04506255 -
Silicone Taping for the Improvement of Abdominal Donor Site Scars
|
N/A | |
Not yet recruiting |
NCT04593706 -
Comparison of the Efficacy of Different Steroids in the Treatment of Abnormal Scars (Keloids, Hypertrophic Scars)
|
N/A | |
Completed |
NCT04643223 -
Effect of Elastic Bandage With Tension on the Inflammatory Response of Hypertrophic Scars
|
N/A | |
Completed |
NCT03986346 -
The Vascularity Changes of Scars With Laser Therapy
|
N/A | |
Completed |
NCT04619589 -
Characterization of Dyschromic Hypertrophic Scar
|
||
Completed |
NCT06347081 -
Effect of Nd-YAG Laser on Hypertrophic Scar
|
N/A | |
Completed |
NCT05412745 -
Class I Medical Device on Post-surgical Scars
|
N/A | |
Terminated |
NCT03403621 -
Hypertrophic Scar Prevention by Novel Topical Gel Application
|
Phase 1/Phase 2 | |
Completed |
NCT00754247 -
A Randomized Comparative Study Evaluating the Tolerability and Efficacy of Two Topical Therapies for the Treatment of Keloids and Hypertrophic Scars
|
Phase 4 | |
Recruiting |
NCT03692273 -
Randomized Control Trial of CO2 Laser to Treat Hypertrophic Burn Scar
|
N/A | |
Completed |
NCT03795116 -
Light Emitting Diode-Red Light (LED-RL) Phototherapy for Skin Scarring Prevention
|
Phase 2 | |
Not yet recruiting |
NCT03850119 -
Nanofat on Wound Healing and Scar Formation
|
N/A |